S49076 . HCl

CHF 96.00
In stock
SYN-1217-M0011 mgCHF 96.00
SYN-1217-M0055 mgCHF 180.00
SYN-1217-M01010 mgCHF 299.00
SYN-1217-M05050 mgCHF 898.00
SYN-1217-M100100 mgCHF 1'496.00
 
More Information
Product Details
Synonyms S-49076 . HCl; (Z)-3-((3-((4-(Morpholinomethyl)-1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)methyl)thiazolidine-2,4-dione hydrochloride
Product Type Chemical
Properties
Formula C22H23ClN4O4S
MW 475.0
CAS 1265965-19-2
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: MET, AXL, FGFR | Kinase Group: TK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key FPSAJUOIYZSJJA-NAIZSXBXSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
S49076 is a novel, potent inhibitor of MET, AXL/MER and FGFR1/2/3. It can potently block cellular phosphorylation of MET, AXL and FGFRs and inhibit downstream signalling in vitro and in vivo. S49076 can inhibit the proliferation of MET- and FGFR2-dependent gastric cancer cells, block MET-driven migration of lung carcinoma cells, and inhibit colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL. S49076 has also been shown to cause tumour growth arrest in bevacizumab-resistant tumours in xenograft models.
Product References
  1. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab: M.F. Burbridge, et al.; Mol. Cancer Ther. 12, 1749 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.